Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

CRISPR Treatment Against Triple-Negative Breast Cancer Attracts Attention

CRISPR Treatment Against Triple-Negative Breast Cancer Attracts Attention

Genome editingis considered among the most effective cancer treatments of the near future. In September 2019, PNAS published research developing a CRISPR treatment system against a type of breast cancer, triple-negative breast cancer . Nanolipogel delivered the CRISPR system, successfully halting tumor growth in mice.

Triple-negative breast cancer accounts for 12% of all breast cancers. These cells lack estrogen, progesterone and HER 2 receptors . This type tends to proliferate and spread faster, and effective approaches are needed because treatment options are very limited.

What Is CRISPR / Cas9?

The greatest challenge in CRISPR genome editing has been the lack of effective delivery systems: getting the tiny gene-editing molecules into target cells is difficult. Virusesare not preferred because they cannot carry large quantities of drugs and may cause side effects. Another method encloses CRISPR in cationic polymer or lipid nanoparticles . However, these components may be toxic to cells. CRISPR is also often retained and degraded by the body before reaching its target.

In this new study, the CRISPR system was placed in a soft nanolipogel .

Nanolipogel is made of nontoxic fatty acids and hydrogels. Antibodies recognizing the cancer cell-surface protein ICAM1 are added to its surface to enable tumor targeting. ICAM1 is an important drug target in triple-negative breast cancer.

structure and biomechanism of nanolipogel used in in vivo crispr genome editing

Once nanolipogel enters the cell, the CRISPR system acts on lipocalin 2 by inhibiting the oncogene’s activity. Lipocalin 2 is an important oncogene supporting breast cancer progression and metastasis in this disease.

After CRISPR treatment in mouse tumor models, cancer aggressiveness and metastasis were inhibited, with no toxicity (side effects) observed.

With 81% success, the developed CRISPR system silenced the lipocalin 2 gene. Tumor growth in mouse models was inhibited by rates up to 77% in the study.

What Does This Study Mean?

  • A nanolipogel capable of safely delivering CRISPR to tissues was developed.
  • This treatment is thought potentially usable for pediatric cancers and capable of carrying other drugs as well.
  • Using nanolipogel may improve CRISPR delivery to tumors.

Sources

Peng Guo, Jiang Yang, Jing Huang, Debra T. Auguste, and Marsha A. Moses.
Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
PNAS, 10 September 2019.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

CRISPR Treatment Against Triple-Negative Breast Cancer Attracts Attention

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy